Sarah Bowen Selected Research

Substance-Related Disorders (Drug Abuse)

1/2023	Efficacy of mindfulness-based relapse prevention in a sample of veterans in a substance use disorder aftercare program: A randomized controlled trial.
9/2022	Trauma-Integrated Mindfulness-Based Relapse Prevention for Women with Comorbid Post-Traumatic Stress Disorder and Substance Use Disorder: A Cluster Randomized Controlled Feasibility and Acceptability Trial.
12/2021	The Role of Pretreatment Expectancy on Substance Use Outcomes in Women Mandated to Mindfulness-Based Relapse Prevention.
10/2020	Approach coping and substance use outcomes following mindfulness-based relapse prevention among individuals with negative affect symptomatology.
8/2019	Individual gender and group gender composition as predictors of differential benefit from mindfulness-based relapse prevention for substance use disorders.
6/2019	An open trial of rolling admission mindfulness-based relapse prevention (Rolling MBRP): feasibility, acceptability, dose-response relations, and mechanisms.
1/2018	Race/ethnicity and racial group composition moderate the effectiveness of mindfulness-based relapse prevention for substance use disorder.
1/2018	Dispositional mindfulness, anticipation and abstinence symptoms related to hypnotic dependence among insomniac women who seek treatment: A cross-sectional study.
11/2017	Baseline patterns of substance use disorder severity and depression and anxiety symptoms moderate the efficacy of mindfulness-based relapse prevention.
7/2017	Mindfulness-Based Relapse Prevention for Methadone Maintenance: A Feasibility Trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sarah Bowen Research Topics

Disease

18	Substance-Related Disorders (Drug Abuse) 01/2023 - 09/2006
3	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 09/2022 - 01/2019
3	Sleep Initiation and Maintenance Disorders (Insomnia) 06/2022 - 01/2018
3	Opioid-Related Disorders (Opiate Addiction) 07/2020 - 03/2015
2	Coronary Disease (Coronary Heart Disease) 03/2024 - 10/2023
2	Chronic Pain 07/2020 - 08/2005
2	Alcoholism (Alcohol Abuse) 01/2012 - 02/2011
1	Cardiovascular Diseases (Cardiovascular Disease) 03/2024
1	Wounds and Injuries (Trauma) 09/2022
1	Cognitive Dysfunction 06/2022
1	Pain (Aches) 07/2020

Drug/Important Bio-Agent (IBA)

3	Hypnotics and Sedatives (Sedatives)IBA 06/2022 - 01/2018
2	2-methylcyclopentadienyl manganese tricarbonyl (MMT)IBA 07/2017 - 01/2012
1	4-toluenesulfonyl fluoride (TSF)IBA 01/2023
1	Opioid Analgesics (Opioids)IBA 07/2020
1	Opiate AlkaloidsIBA 10/2019
1	EndocannabinoidsIBA 01/2019
1	Methadone (Dolophine)FDA LinkGeneric 07/2017
1	Heroin (Diamorphine)IBA 11/2012

Therapy/Procedure

15	Secondary Prevention 01/2023 - 10/2009
3	Meditation 01/2023 - 09/2006
2	Therapeutics 07/2017 - 08/2005
1	Percutaneous Coronary Intervention 03/2024
1	Cardiac Rehabilitation 10/2023
1	Self Medication 01/2019
1	Opiate Substitution Treatment 03/2015
1	Drug Therapy (Chemotherapy) 02/2011